Companies /Healthcare

Novavax Inc

NASDAQ: NVAX Biotechnology
$9.26
â–² $0.21 (+2.32%) today
Markets closed · 6:13pm ET
Today · % change

24/7 Wall St. View

Fundamentals

Market Cap
$1.5B
Profit Margin
-59.9%
Revenue (TTM)
$413.8M
EPS (TTM)
$-1.53
52-Week Range
$6 – $12
Street Target
$14.00

About Novavax

Novavax Inc is a biotechnology firm focused on enhancing global health by creating vaccines for serious infectious diseases. It uses innovative technologies like recombinant protein, nanoparticle technology, and its unique Matrix-M adjuvant to boost immune responses. The company has developed a COVID-19 vaccine, marketed under various names, for adults and adolescents. Additionally, Novavax is working on vaccines for influenza and a combination of influenza and COVID-19, as well as a malaria vaccine. Founded in 1987, Novavax is based in Gaithersburg, Maryland.

NVAX Coverage

8:57am ET
Investing

Friday’s Top Analyst Upgrades and Downgrades: Alphabet, Citizens Financial, Emerson Electric, GE, Las Vega Sands, Medical Properties Trust, Microsoft, Nio, Raytheon, Tesla and More

Friday's top analyst upgrades and downgrades included Alphabet, Chegg, Citizens Financial, Comstock Resources, Coterra Energy, CubeSmart, Emerson Electric, Fastly, General Electric, Las Vega Sands, Medical Properties Trust, Microsoft, Nio, Novavax, Raytheon Technologies,…

Lee Jackson